Equity · Healthcare
Guardant Health, Inc. (GH) perpetual futures
Guardant Health is a precision oncology company providing liquid biopsy blood tests, clinical-genomic datasets, and analytical solutions for cancer patients and biopharmaceutical clients.
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:GH
Loads TradingView's third-party widget (about 1 MB) on demand.
Trading data
Perpetual market activity
0/1 live markets
Trading data
Perpetual market activity
Spot performance
Best venues for this underlying
Best liquidity
-Tightest spread
-Highest volume
-Next catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $203.40 |
| 12-month target range (low – high) | $180 – $225 |
| Ratings in the provider's consensus | 31 |
Price targets as of 2026-11-21
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 4 | 21 | 0 | 0 | 1 |
| Oct 2026 | 5 | 21 | 0 | 1 | 1 |
| Sep 2026 | 5 | 21 | 0 | 0 | 1 |
| Aug 2026 | 5 | 19 | 0 | 0 | 1 |
| Jul 2026 | 5 | 19 | 0 | 1 | 1 |
| Jun 2026 | 5 | 19 | 1 | 0 | 1 |
| May 2026 | 4 | 16 | 2 | 0 | 1 |
| Apr 2026 | 5 | 16 | 2 | 0 | 0 |
| Mar 2026 | 5 | 17 | 2 | 0 | 0 |
| Feb 2026 | 5 | 17 | 2 | 1 | 1 |
| Jan 2026 | 5 | 17 | 1 | 1 | 1 |
| Dec 2025 | 5 | 17 | 0 | 1 | 1 |
Ownership
Institutional · 2026-Q2Reference market activity
GH-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25Chief People Officer Terilyn J. Monroe sold 3,842 Guardant Health common shares in 5 open-market sales on Nov 18, 2026 at prices from $140.64 to $144.58, leaving 21,058 shares held.
Director Hidalgo Medina Manuel converted 232 restricted stock units into 232 common shares of Guardant Health, leaving 5,484 common shares owned directly.
Director Alex M. Azar II sold 69 shares of Guardant Health common stock (code S) at $149.56 in one transaction, leaving 962 shares directly owned.
Director Tariq Musa converted 250 restricted stock units into 250 common shares (M-Exempt) and sold 116 common shares at $149.56, leaving 11,717 shares held.
Guardant Health director Azar Alex M II converted 138 restricted stock units into 138 common shares on 2026-11-12, leaving 4,678 RSUs and 1,031 shares held after.
Director Kevin R. Sayer received an award of 3,149 restricted stock units at $0.00, an A-Award (compensation grant, not a purchase); he held 3,149 units after.
Form 3 for director Kevin R. Sayer of Guardant Health reports no reportable shares: one Common Stock line with 0 shares at $0.00, leaving 0 owned.
Guardant Health Chief Accounting Officer Robert Parks was awarded 18,893 restricted stock units on Nov 9, 2026, per a Form 4 filed Nov 12. The award was granted at $0.00 and is compensation, not an open-market purchase.
Form 3 for Robert Parks, Guardant Health's Chief Accounting Officer, filed 2026-11-12, reports no shares acquired or disposed in the reported transaction; 0 shares of Common Stock at $0.00.
Director Roberto Mignone reported an M-Exempt exercise converting 264 Restricted Stock Units into 264 shares of Guardant Health common stock at $0.00, leaving 10,538 shares owned.
Director Hidalgo Medina Manuel converted 232 restricted stock units into 232 shares of Guardant Health common stock via an exempt RSU exercise; no open-market purchase or sale occurred. He held 5,252 common shares afterward.
Director Tariq Musa converted 250 restricted stock units into 250 common shares and sold 116 common shares at $165.88, leaving 11,583 shares directly owned.
Director Alex M. Azar II sold 69 shares of Guardant Health common stock on the open market at $159.89 each, leaving 893 shares owned after the sale.
Filings
35 · Latest SEC filingsChief People Officer Terilyn J. Monroe sold 3,842 Guardant Health common shares in 5 open-market sales on Nov 18, 2026 at prices from $140.64 to $144.58, leaving 21,058 shares held.
Director Hidalgo Medina Manuel converted 232 restricted stock units into 232 common shares of Guardant Health, leaving 5,484 common shares owned directly.
Director Alex M. Azar II sold 69 shares of Guardant Health common stock (code S) at $149.56 in one transaction, leaving 962 shares directly owned.
Director Tariq Musa converted 250 restricted stock units into 250 common shares (M-Exempt) and sold 116 common shares at $149.56, leaving 11,717 shares held.
Guardant Health director Azar Alex M II converted 138 restricted stock units into 138 common shares on 2026-11-12, leaving 4,678 RSUs and 1,031 shares held after.
Director Kevin R. Sayer received an award of 3,149 restricted stock units at $0.00, an A-Award (compensation grant, not a purchase); he held 3,149 units after.
Form 3 for Robert Parks, Guardant Health's Chief Accounting Officer, filed 2026-11-12, reports no shares acquired or disposed in the reported transaction; 0 shares of Common Stock at $0.00.
Form 3 for director Kevin R. Sayer of Guardant Health reports no reportable shares: one Common Stock line with 0 shares at $0.00, leaving 0 owned.
Guardant Health Chief Accounting Officer Robert Parks was awarded 18,893 restricted stock units on Nov 9, 2026, per a Form 4 filed Nov 12. The award was granted at $0.00 and is compensation, not an open-market purchase.
Director Roberto Mignone reported an M-Exempt exercise converting 264 Restricted Stock Units into 264 shares of Guardant Health common stock at $0.00, leaving 10,538 shares owned.
Director Hidalgo Medina Manuel converted 232 restricted stock units into 232 shares of Guardant Health common stock via an exempt RSU exercise; no open-market purchase or sale occurred. He held 5,252 common shares afterward.
Director Tariq Musa converted 250 restricted stock units into 250 common shares and sold 116 common shares at $165.88, leaving 11,583 shares directly owned.
Director Alex M. Azar II sold 69 shares of Guardant Health common stock on the open market at $159.89 each, leaving 893 shares owned after the sale.
Director Alex M. Azar II converted 137 restricted stock units into 137 common shares of Guardant Health on Oct 12, 2026, with no open-market purchase. He held 962 common shares afterward.
Guardant Health officer Chris Freeman converted 7,416 restricted stock units into common stock and had 3,143 shares withheld for taxes at $174.75. He held 69,647 shares after the transactions.
Guardant Health CTO Darya Chudova converted 8,033 restricted stock units into shares of common stock on Oct 1, 2026, and 4,320 shares were withheld for taxes at $174.75.
CFO Michael Brian Bell converted 7,280 restricted stock units into 7,280 common shares and had 3,914 shares withheld for taxes at $174.75, leaving 55,182 shares owned.
Guardant Health CEO AmirAli Talasaz converted 36,530 RSUs into 36,530 common shares and had 18,515 shares withheld for taxes at $174.75-$178.36. He still holds about 1.83M common shares.
Guardant Health CEO Helmy Eltoukhy converted 36,530 RSUs into 36,530 common shares across three exempt exercises, and 18,515 shares were withheld for tax at $174.75-$178.36.
Guardant Health officer John G. Saia converted 6,089 restricted stock units into 7,063 common shares (M-Exempt) and had 3,706 shares withheld for taxes at $174.75 (F-InKind).
Guardant Health officer Terilyn J. Monroe exercised 4,019 restricted stock units into common stock, then 2,098 shares were withheld for taxes at $174.75.
Guardant Health officer Kalia Kumud converted 4,439 restricted stock units into 6,046 common shares on 2026-10-01, with 3,067 shares withheld for taxes at $174.75.
Director Roberto Mignone converted 264 RSUs into 264 common shares of Guardant Health on 2026-09-21 (M-Exempt), leaving 6,600 RSUs and 10,274 common shares held.
Director Manuel Hidalgo Medina converted 232 restricted stock units into 232 common shares via an exempt M-Exempt transaction on 2026-09-17; he held 5,020 common shares afterward.
Director Azar Alex M II sold 826 common shares of Guardant Health at $175 per share on Sep 16, 2026, leaving 825 shares directly owned.
Director Tariq Musa converted 249 restricted stock units (M-Exempt) into 249 common shares and sold 116 common shares at $175, leaving 11,449 shares owned.
Guardant Health CTO Darya Chudova sold 7,738 common shares at $178 on Sept 15, 2026, leaving 70,635 shares owned.
Director Krognes Steve E. sold 6,674 Guardant Health common shares (S-Sale) on 2026-09-16 in four open-market trades at $174.46-$177.48, leaving 7,906 shares owned.
Director Alex M. Azar II converted 1,651 restricted stock units into 1,651 common shares of Guardant Health via an exempt exercise on 2026-09-12. No open-market purchase or sale occurred.
Transcripts
Earnings callsFY2026 Q32026-11-05
Earnings calls
AI summary
positiveGuardant Health reported third quarter 2026 revenue of $361 million, up 36% year-over-year, with oncology revenue of $231 million (+25%), biopharma and data revenue of $59 million (+8%), and screening revenue of $68 million (+180%). Oncology test volume rose 58% to 117,000, Shield volume rose 246% to 83,000, and Shield ASP was above $800. The company raised full-year 2026 revenue guidance to $1.36 billion to $1.37 billion, representing approximately 38% to 40% growth. Management also updated full-year free cash flow burn guidance to $205 million to $220 million due to a temporary CMS claims processing delay for the new Guardant360 Liquid CDx billing code, and reiterated confidence in company-wide free cash flow breakeven by the end of 2027.
Key takeaways
- Q3 revenue grew 36% to $361 million, with oncology revenue up 25% to $231 million, biopharma and data revenue up 8% to $59 million, and screening revenue up 180% to $68 million.
- Oncology test volume grew 58% to 117,000; Guardant360 Liquid volume grew nearly 30%, Guardant360 Tissue had record sequential growth, and Reveal volume grew well in excess of 100%.
- Shield volume grew 246% to 83,000 tests, and Shield cost per test fell to $330 in Q3 from $410 in Q2, surpassing the year-end target of $350 a quarter early.
- The company received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH and submitted a PMA for Guardant360 Tissue.
- Coverage wins from UnitedHealthcare, Carelon, EviCore and regional payers add approximately 30 million covered lives for Shield, and the company estimates approximately 100 million people will be covered entering 2027.
Financial highlights
- Third quarter revenue was $361 million, up 36% from $265 million a year ago.
- Third quarter non-GAAP gross margin was 67%, up from 66% a year ago; non-GAAP operating expenses were $287 million, up 26%.
- Adjusted EBITDA loss was $37 million, an improvement of $8 million year-over-year; free cash flow burn was $37 million, an improvement of $9 million.
- Quarter-end cash and investments were $1.1 billion.
Guidance
- Full year 2026 revenue guidance raised to $1.36 billion to $1.37 billion, representing approximately 38% to 40% year-over-year growth.
- Oncology revenue growth of approximately 30% and volume growth of more than 50%; biopharma and data growth unchanged at low double digits.
- Screening revenue guidance raised to $233 million to $238 million with 285,000 to 290,000 field tests; full year non-GAAP gross margin expected at 65%.
- Full year 2026 non-GAAP operating expenses expected at approximately $1.105 billion to $1.125 billion; free cash flow burn expected at $205 million to $220 million, reflecting a $10 million to $15 million CMS claims timing shift into the first half of 2027.
Q&A themes
- ESR1 companion diagnostic approval and expectations for repeat testing and therapy switching with Guardant360.
- Shield seasonality, adoption drivers including rep productivity, Quest collaboration, DTC campaigns and ACS guideline inclusion.
- Shield ASP sustainability above $800 and potential mix-driven decline as commercial under-65 patients increase.
- Reveal Ultra clinical launch, MRD study ramp and reimbursement pathway, including Medicare coverage.
Risks
- CMS cannot process claims for the new Guardant360 Liquid CDx billing code until January 2027, shifting an estimated $10 million to $15 million in payments to the first half of 2027.
- Shield ASP may tick down as the mix shifts toward commercially insured under-65 patients ahead of revenue recognition from commercial payers.
- NCD coverage does not currently align with the quarterly testing frequency in the ETCAMAH protocol, and updating the NCD is the main pathway to reimbursement for that frequency.
FY2026 Q22026-07-30
Earnings calls
AI summary
positiveGuardant Health reported Q2 2026 revenue of $335 million, up 44% year-over-year, with broad-based growth across Oncology, Biopharma & Data and Screening. Oncology revenue was $219 million (+38%) on roughly 104,000 tests (+63%), with Reveal growing over 100% and Guardant360 Liquid over 30%. Biopharma & Data posted record revenue of $61 million (+9%). Screening revenue was $53 million on about 66,000 Shield tests versus $15 million and 16,000 tests a year ago. The company cited FDA approval of Guardant360 Liquid CDx and a higher-throughput, lower-COGS Shield workflow, Shield inclusion in American Cancer Society guidelines, and a UnitedHealth Group coverage decision effective August 1. Guardant raised FY2026 revenue guidance to $1.34-$1.36 billion (36%-38% growth) and Screening revenue guidance to $218-$230 million.
Key takeaways
- Q2 2026 total revenue reached $335 million, up 44% year-over-year, with growth described as broad-based across Oncology, Biopharma & Data and Screening.
- Oncology test volume rose 63% to approximately 104,000 tests; Reveal was the fastest-growing product with volume more than doubling year-over-year, and Guardant360 Liquid grew over 30%.
- Screening revenue was $53 million on approximately 66,000 Shield tests, versus $15 million and approximately 16,000 tests in Q2 2025.
- Guardant received FDA approval for Guardant360 Liquid CDx and began a phased U.S. rollout in June, with widespread availability planned after ADLT designation, which it expects in the first half of 2027.
- Shield was included in American Cancer Society colorectal cancer screening guidelines and UnitedHealth Group will cover Shield for adults 45 and older effective August 1; management estimates roughly 70 million lives, about 60% of the market, are now covered.
Financial highlights
- Q2 2026 revenue was $335 million, up 44% year-over-year.
- Oncology revenue was $219 million (+38%) on approximately 104,000 tests (+63%).
- Biopharma & Data revenue was a record $61 million, up 9% year-over-year.
- Non-GAAP gross margin was 67% versus 66% a year ago; adjusted EBITDA loss was $56 million and Q2 free cash flow burn was $70 million, with approximately $1.2 billion in cash and investments at quarter end.
Guidance
- Full year 2026 revenue guidance raised to $1.34-$1.36 billion, representing growth of 36% to 38%.
- Oncology guidance: approximately 30% revenue growth and approximately 50% volume growth; Biopharma & Data outlook unchanged at low double-digit growth.
- Screening revenue guidance raised to $218-$230 million with 270,000 to 285,000 Shield tests; full year non-GAAP gross margin outlook remains 64% to 65%.
- 2026 non-GAAP operating expenses now expected at $1.08-$1.1 billion (20%-22% growth), and full year free cash flow burn of $195-$205 million; company remains committed to company-wide cash flow breakeven by the end of 2027.
Q&A themes
- Impact of UnitedHealth coverage and ACS guideline inclusion on Shield ASP, volume and commercial payer conversations, including timing relative to USPSTF.
- Oncology volume drivers and the raised 50% volume growth guide, including Reveal therapy monitoring cadence and tough Guardant360 comparisons in the second half.
- Potential Guardant360 ADLT pricing of $8,455 versus the current $5,000 Medicare price, timing of payer flow-through, and how much incremental gross profit is reinvested versus dropped to the bottom line.
- Reveal Ultra development and launch strategy, plus timing of MolDX reimbursement decisions for breast, immuno-oncology and chemotherapy monitoring.
Risks
- Shield ASP impact from commercial coverage is expected to take time, and pricing with UnitedHealth has not been finalized.
- Management does not expect additional major payer wins for the rest of the year and has not included any in guidance.
- Free cash flow burn guidance rose by $10 million due to CapEx investment in Shield lab capacity, and company-wide cash flow breakeven is targeted for the end of 2027.
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Company data
Company intelligence
Updated: Nov 22, 2026, 01:23 AM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Chief executive
- Helmy Eltoukhy
- Employees
- 2,498
- IPO date
- Oct 4, 2018
- Country
- US
- Exchange
- NASDAQ Global Select
Rating factors
- Return on equityi
- 5/5
- Return on assetsi
- 1/5
- Debt to equityi
- 1/5
- Price to earningsi
- 1/5
- Price to booki
- 1/5
Company press releases
Congressional disclosures
Senate
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| ANNPX | 1.21% | 10.6M |
| VTI | 0.03% | 3.2M |
| NJM | 0.47% | 2.9M |
| VB | 0.28% | 2.9M |
| NCV | 0.76% | 2.6M |
| NFJ | 0.31% | 2M |
| NIE | 0.45% | 2M |
| NCZ | 0.77% | 2M |
| VBK | 0.66% | 1.6M |
| VXF | 0.29% | 1.5M |
| ACV | 0.69% | 1.5M |
| NLO | 0.89% | 1M |
Analyst track record
How the analysts covering GH have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 169 | 409 |
| Analysts | 31 | 41 |
| Buy / hold / sell | 165 / 4 / 0 | 404 / 5 / 0 |
| Upgrades / downgrades / initiations | 1 / 1 / 6 | 3 / 1 / 13 |
| Price targets hit / missed | 79 / 73 (52%) | 280 / 73 (79%) |
| Avg. return after a rating (TipRanks) | +0.2% | +117.4% |
| Best / worst call | +78.5% / -32.6% | +911.3% / -32.6% |
After buy calls on this stock: median 21-day move +3.3% vs S&P 500 +3.4% (n = 404)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Daniel BrennanTD Cowen100% hit rate on this stock · 14 targets measuredBuytarget $220Nov 6, 2026
- Michael RyskinBank of America Securities100% hit rate on this stock · 12 targets measuredBuytarget $200Oct 9, 2026
- Luke SergottBarclays100% hit rate on this stock · 11 targets measuredBuytarget $220Nov 6, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 18, 2026 | Eve BursteinBernsteinNov 18, 2026 | BuyMaintained | $190↗ | article ↗ |
| Nov 10, 2026 | David WestenbergPiper SandlerNov 10, 2026 | BuyReiterated | $190↗ | article ↗ |
| Nov 6, 2026 | Lu LiBank of America SecuritiesNov 6, 2026 | BuyMaintained | –↗ | article ↗ |
| Nov 6, 2026 | Daniel AriasStifel NicolausNov 6, 2026 | BuyMaintained | $180↗ | article ↗ |
| Nov 6, 2026 | Evie KosloskyGoldman SachsNov 6, 2026 | BuyMaintained | $210↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 19, 2026 · 169 ratings
BingX